Pub Date : 2024-09-19DOI: 10.1038/s41569-024-01089-9
Irene Fernández-Ruiz
In patients with heart failure and secondary mitral valve regurgitation, transcatheter edge-to-edge repair is non-inferior to mitral valve surgery with respect to a composite of death, hospitalization for heart failure, reintervention, implantation of an assist device or stroke at 1 year after the procedure, according to findings from the MATTERHORN trial.
{"title":"TEER is non-inferior to surgery in patients with secondary mitral regurgitation","authors":"Irene Fernández-Ruiz","doi":"10.1038/s41569-024-01089-9","DOIUrl":"10.1038/s41569-024-01089-9","url":null,"abstract":"In patients with heart failure and secondary mitral valve regurgitation, transcatheter edge-to-edge repair is non-inferior to mitral valve surgery with respect to a composite of death, hospitalization for heart failure, reintervention, implantation of an assist device or stroke at 1 year after the procedure, according to findings from the MATTERHORN trial.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"21 11","pages":"742-742"},"PeriodicalIF":41.7,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142245401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-19DOI: 10.1038/s41569-024-01080-4
Gregory B. Lim
In the NOTION-3 trial, percutaneous coronary intervention reduced the occurrence of major adverse cardiac events compared with conservative treatment in patients who were undergoing transcatheter aortic valve implantation for severe aortic stenosis and who had stable coronary artery disease.
{"title":"Combining TAVI with PCI in patients with aortic stenosis and CAD","authors":"Gregory B. Lim","doi":"10.1038/s41569-024-01080-4","DOIUrl":"10.1038/s41569-024-01080-4","url":null,"abstract":"In the NOTION-3 trial, percutaneous coronary intervention reduced the occurrence of major adverse cardiac events compared with conservative treatment in patients who were undergoing transcatheter aortic valve implantation for severe aortic stenosis and who had stable coronary artery disease.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"21 11","pages":"742-742"},"PeriodicalIF":41.7,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142245407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-19DOI: 10.1038/s41569-024-01086-y
Gregory B. Lim
Data from the HELIOS-B trial show that RNA interference with vutrisiran reduces the risk of death and recurrent cardiovascular events in patients with transthyretin amyloidosis with cardiomyopathy.
{"title":"Benefit of vutrisiran in transthyretin amyloidosis with cardiomyopathy","authors":"Gregory B. Lim","doi":"10.1038/s41569-024-01086-y","DOIUrl":"10.1038/s41569-024-01086-y","url":null,"abstract":"Data from the HELIOS-B trial show that RNA interference with vutrisiran reduces the risk of death and recurrent cardiovascular events in patients with transthyretin amyloidosis with cardiomyopathy.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"21 11","pages":"740-740"},"PeriodicalIF":41.7,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142245400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-17DOI: 10.1038/s41569-024-01082-2
Karina Huynh
A single combined measurement of high-sensitivity C-reactive protein, LDL-cholesterol and lipoprotein(a) levels in plasma predicts incident cardiovascular events among women over a 30-year follow-up period, according to a new study.
一项新的研究表明，对血浆中的高敏 C 反应蛋白、低密度脂蛋白胆固醇和脂蛋白（a）水平进行一次联合测量，就能预测女性在 30 年随访期内发生的心血管事件。
{"title":"Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women","authors":"Karina Huynh","doi":"10.1038/s41569-024-01082-2","DOIUrl":"10.1038/s41569-024-01082-2","url":null,"abstract":"A single combined measurement of high-sensitivity C-reactive protein, LDL-cholesterol and lipoprotein(a) levels in plasma predicts incident cardiovascular events among women over a 30-year follow-up period, according to a new study.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"21 11","pages":"741-741"},"PeriodicalIF":41.7,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142235046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-17DOI: 10.1038/s41569-024-01073-3
Job A. J. Verdonschot, Aimee D. C. Paulussen, Neal K. Lakdawala, Christine E. M. de Die-Smulders, James S. Ware, Jodie Ingles
In the past decade, genetic testing for cardiac disease has become part of routine clinical care. A genetic diagnosis provides the possibility to clarify risk for relatives. For family planning, a genetic diagnosis provides reproductive options, including prenatal diagnosis and preimplantation genetic testing, that can prevent an affected parent from having a child with the genetic predisposition. Owing to the complex genetic architecture of cardiac diseases, characterized by incomplete disease penetrance and the interplay between monogenic and polygenic variants, the risk reduction that can be achieved using reproductive genetic testing varies among individuals. Globally, disparities, including regulatory and financial barriers, in access to reproductive genetic tests exist. Although reproductive options are gaining a prominent position in the management of patients with inherited cardiac diseases, specific policies and guidance are lacking. Guidelines recommend that prenatal diagnosis and preimplantation genetic testing are options that should be discussed with families. Health-care professionals should, therefore, be aware of the possibilities and feel confident to discuss the benefits and challenges. In this Review, we provide an overview of the reproductive options in the context of inherited cardiac diseases, covering the genetic, technical, psychosocial and equity considerations, to prepare health-care professionals for discussions with their patients. Genetic testing for inherited cardiac disease has become part of routine clinical care. In this Review, Verdonschot et al. provide an overview of the reproductive options in the context of monogenic cardiac diseases, with a focus on preimplantation genetic testing, to prepare health-care professionals for discussions with their patients.
{"title":"Reproductive options and genetic testing for patients with an inherited cardiac disease","authors":"Job A. J. Verdonschot, Aimee D. C. Paulussen, Neal K. Lakdawala, Christine E. M. de Die-Smulders, James S. Ware, Jodie Ingles","doi":"10.1038/s41569-024-01073-3","DOIUrl":"10.1038/s41569-024-01073-3","url":null,"abstract":"In the past decade, genetic testing for cardiac disease has become part of routine clinical care. A genetic diagnosis provides the possibility to clarify risk for relatives. For family planning, a genetic diagnosis provides reproductive options, including prenatal diagnosis and preimplantation genetic testing, that can prevent an affected parent from having a child with the genetic predisposition. Owing to the complex genetic architecture of cardiac diseases, characterized by incomplete disease penetrance and the interplay between monogenic and polygenic variants, the risk reduction that can be achieved using reproductive genetic testing varies among individuals. Globally, disparities, including regulatory and financial barriers, in access to reproductive genetic tests exist. Although reproductive options are gaining a prominent position in the management of patients with inherited cardiac diseases, specific policies and guidance are lacking. Guidelines recommend that prenatal diagnosis and preimplantation genetic testing are options that should be discussed with families. Health-care professionals should, therefore, be aware of the possibilities and feel confident to discuss the benefits and challenges. In this Review, we provide an overview of the reproductive options in the context of inherited cardiac diseases, covering the genetic, technical, psychosocial and equity considerations, to prepare health-care professionals for discussions with their patients. Genetic testing for inherited cardiac disease has become part of routine clinical care. In this Review, Verdonschot et al. provide an overview of the reproductive options in the context of monogenic cardiac diseases, with a focus on preimplantation genetic testing, to prepare health-care professionals for discussions with their patients.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"22 3","pages":"199-211"},"PeriodicalIF":41.7,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142235050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-17DOI: 10.1038/s41569-024-01081-3
Jennifer Harman
New research suggests that the presence of clonal haematopoiesis is unidirectionally associated with the development of atherosclerosis and that colchicine holds potential therapeutic value.
新的研究表明，克隆性造血与动脉粥样硬化的发生具有单向性，秋水仙碱具有潜在的治疗价值。
{"title":"Clonal haematopoiesis: an emerging causal risk factor for atherosclerotic CVD","authors":"Jennifer Harman","doi":"10.1038/s41569-024-01081-3","DOIUrl":"10.1038/s41569-024-01081-3","url":null,"abstract":"New research suggests that the presence of clonal haematopoiesis is unidirectionally associated with the development of atherosclerosis and that colchicine holds potential therapeutic value.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"21 11","pages":"741-741"},"PeriodicalIF":41.7,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142235047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-17DOI: 10.1038/s41569-024-01070-6
My Phung Khuu, Nadja Paeslack, Olga Dremova, Corinne Benakis, Klytaimnistra Kiouptsi, Christoph Reinhardt
The gut microbiota has emerged as an environmental risk factor that affects thrombotic phenotypes in several cardiovascular diseases. Evidence includes the identification of marker species by sequencing studies of the gut microbiomes of patients with thrombotic disease, the influence of antithrombotic therapies on gut microbial diversity, and preclinical studies in mouse models of thrombosis that have demonstrated the functional effects of the gut microbiota on vascular inflammatory phenotypes and thrombus formation. In addition to impaired gut barrier function promoting low-grade inflammation, gut microbiota-derived metabolites have been shown to act on vascular cell types and promote thrombus formation. Therefore, these meta-organismal pathways that link the metabolic capacities of gut microorganisms with host immune functions have emerged as potential diagnostic markers and novel drug targets. In this Review, we discuss the link between the gut microbiota, its metabolites and thromboembolic diseases. The gut microbiota has emerged as a risk factor that affects thrombotic phenotypes in several cardiovascular diseases. In this Review, Reinhardt and colleagues discuss the link between the gut microbiota, its metabolites and thromboembolic diseases, and summarize potential therapeutic interventions to modulate the gut microbiota.
{"title":"The gut microbiota in thrombosis","authors":"My Phung Khuu, Nadja Paeslack, Olga Dremova, Corinne Benakis, Klytaimnistra Kiouptsi, Christoph Reinhardt","doi":"10.1038/s41569-024-01070-6","DOIUrl":"10.1038/s41569-024-01070-6","url":null,"abstract":"The gut microbiota has emerged as an environmental risk factor that affects thrombotic phenotypes in several cardiovascular diseases. Evidence includes the identification of marker species by sequencing studies of the gut microbiomes of patients with thrombotic disease, the influence of antithrombotic therapies on gut microbial diversity, and preclinical studies in mouse models of thrombosis that have demonstrated the functional effects of the gut microbiota on vascular inflammatory phenotypes and thrombus formation. In addition to impaired gut barrier function promoting low-grade inflammation, gut microbiota-derived metabolites have been shown to act on vascular cell types and promote thrombus formation. Therefore, these meta-organismal pathways that link the metabolic capacities of gut microorganisms with host immune functions have emerged as potential diagnostic markers and novel drug targets. In this Review, we discuss the link between the gut microbiota, its metabolites and thromboembolic diseases. The gut microbiota has emerged as a risk factor that affects thrombotic phenotypes in several cardiovascular diseases. In this Review, Reinhardt and colleagues discuss the link between the gut microbiota, its metabolites and thromboembolic diseases, and summarize potential therapeutic interventions to modulate the gut microbiota.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"22 2","pages":"121-137"},"PeriodicalIF":41.7,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142235049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-17DOI: 10.1038/s41569-024-01078-y
Karina Huynh
Cardiomyocytes can activate the type I interferon response in the infarct border zone after myocardial infarction, indicating that the type I interferon pathway, in addition to its well-established role in antiviral responses, is also involved in cardiac injury.
{"title":"Interferon response at the border zone of the infarcted heart","authors":"Karina Huynh","doi":"10.1038/s41569-024-01078-y","DOIUrl":"10.1038/s41569-024-01078-y","url":null,"abstract":"Cardiomyocytes can activate the type I interferon response in the infarct border zone after myocardial infarction, indicating that the type I interferon pathway, in addition to its well-established role in antiviral responses, is also involved in cardiac injury.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"21 11","pages":"740-740"},"PeriodicalIF":41.7,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142235048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-16DOI: 10.1038/s41569-024-01071-5
Junyan Xu, Junli Guo, Tianxiao Liu, Chongzhe Yang, Zhaojie Meng, Peter Libby, Jinying Zhang, Guo-Ping Shi
Eosinophils are essential innate immune cells in allergic responses. Accumulating evidence indicates that eosinophils also participate in the pathogenesis of cardiovascular diseases (CVDs). In clinical studies, high blood eosinophil counts and eosinophil cationic protein levels have been associated with an increased risk of CVD, including myocardial infarction (MI), cardiac hypertrophy, atrial fibrillation, abdominal aortic aneurysm (AAA) and atherosclerosis. However, low blood eosinophil counts have also been reported to be a risk factor for MI, heart failure, aortic dissection, AAA, deep vein thrombosis, pulmonary embolism and ischaemic stroke. Although these conflicting clinical observations remain unexplained, CVD status, timing of eosinophil data collection, and tissue eosinophil phenotypic and functional heterogeneities might account for these discrepancies. Preclinical studies suggest that eosinophils have protective actions in MI, cardiac hypertrophy, heart failure and AAA. By contrast, cationic proteins and platelet-activating factor from eosinophils have been shown to promote vascular smooth muscle cell proliferation, vascular calcification, thrombomodulin inactivation and platelet activation and aggregation, thereby exacerbating atherosclerosis, atrial fibrillation, thrombosis and associated complications. Therefore, eosinophils seem to promote calcification and thrombosis in chronic CVD but are protective in acute cardiovascular settings. In this Review, we summarize the available clinical and preclinical data on the different roles of eosinophils in CVD. In this Review, Shi and co-workers summarize the available evidence on the role of eosinophils in cardiovascular diseases, highlighting differences between preclinical and clinical findings and placing clinical data in the context of experimental data to discuss potential pathogenic or protective roles of eosinophils in different cardiovascular disease settings.
{"title":"Differential roles of eosinophils in cardiovascular disease","authors":"Junyan Xu, Junli Guo, Tianxiao Liu, Chongzhe Yang, Zhaojie Meng, Peter Libby, Jinying Zhang, Guo-Ping Shi","doi":"10.1038/s41569-024-01071-5","DOIUrl":"10.1038/s41569-024-01071-5","url":null,"abstract":"Eosinophils are essential innate immune cells in allergic responses. Accumulating evidence indicates that eosinophils also participate in the pathogenesis of cardiovascular diseases (CVDs). In clinical studies, high blood eosinophil counts and eosinophil cationic protein levels have been associated with an increased risk of CVD, including myocardial infarction (MI), cardiac hypertrophy, atrial fibrillation, abdominal aortic aneurysm (AAA) and atherosclerosis. However, low blood eosinophil counts have also been reported to be a risk factor for MI, heart failure, aortic dissection, AAA, deep vein thrombosis, pulmonary embolism and ischaemic stroke. Although these conflicting clinical observations remain unexplained, CVD status, timing of eosinophil data collection, and tissue eosinophil phenotypic and functional heterogeneities might account for these discrepancies. Preclinical studies suggest that eosinophils have protective actions in MI, cardiac hypertrophy, heart failure and AAA. By contrast, cationic proteins and platelet-activating factor from eosinophils have been shown to promote vascular smooth muscle cell proliferation, vascular calcification, thrombomodulin inactivation and platelet activation and aggregation, thereby exacerbating atherosclerosis, atrial fibrillation, thrombosis and associated complications. Therefore, eosinophils seem to promote calcification and thrombosis in chronic CVD but are protective in acute cardiovascular settings. In this Review, we summarize the available clinical and preclinical data on the different roles of eosinophils in CVD. In this Review, Shi and co-workers summarize the available evidence on the role of eosinophils in cardiovascular diseases, highlighting differences between preclinical and clinical findings and placing clinical data in the context of experimental data to discuss potential pathogenic or protective roles of eosinophils in different cardiovascular disease settings.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"22 3","pages":"165-182"},"PeriodicalIF":41.7,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142235051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-11DOI: 10.1038/s41569-024-01075-1
Claudia Monaco, Lea Dib
The immune response is not unlike a game of chess, with white and black pieces playing opposing roles and orchestrating an opening, a middle and an endgame of innate immunity, adaptive immunity and resolution, respectively. After decades of research, the study of atheroimmunology has brought the first therapeutics to the clinic. Can we resynchronize the immune system in atherosclerosis and save the king?
{"title":"Atheroimmunology: keeping the immune system in atherosclerosis in check","authors":"Claudia Monaco, Lea Dib","doi":"10.1038/s41569-024-01075-1","DOIUrl":"10.1038/s41569-024-01075-1","url":null,"abstract":"The immune response is not unlike a game of chess, with white and black pieces playing opposing roles and orchestrating an opening, a middle and an endgame of innate immunity, adaptive immunity and resolution, respectively. After decades of research, the study of atheroimmunology has brought the first therapeutics to the clinic. Can we resynchronize the immune system in atherosclerosis and save the king?","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"21 11","pages":"737-738"},"PeriodicalIF":41.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142170767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：